Our top pick for
Sibanye Stillwater Limited is a gold business based in the US. Sibanye Stillwater shares (SBSW) are listed on the NYSE and all prices are listed in US Dollars. Sibanye Stillwater employs 80,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$15.00|
|52-week range||$9.93 - $19.51|
|50-day moving average||$13.99|
|200-day moving average||$16.82|
|Wall St. target price||$20.75|
|Dividend yield||$6.13 (39.78%)|
|Earnings per share (TTM)||$4.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||0.54%|
|1 month (2021-09-20)||16.37%|
|3 months (2021-07-20)||-4.64%|
|6 months (2021-04-20)||-23.51%|
|1 year (2020-10-19)||27.23%|
|2 years (2019-10-18)||117.08%|
|3 years (2018-10-19)||373.19%|
|5 years (2016-10-19)||84.44%|
Valuing Sibanye Stillwater stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sibanye Stillwater's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sibanye Stillwater's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Sibanye Stillwater shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Sibanye Stillwater's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $72.4 billion.
The EBITDA is a measure of a Sibanye Stillwater's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$162.3 billion|
|Operating margin TTM||39.33%|
|Gross profit TTM||$44 billion|
|Return on assets TTM||29.93%|
|Return on equity TTM||71.44%|
|Market capitalisation||$11 billion|
TTM: trailing 12 months
There are currently 8.7 million Sibanye Stillwater shares held short by investors – that's known as Sibanye Stillwater's "short interest". This figure is 15.4% up from 7.5 million last month.
There are a few different ways that this level of interest in shorting Sibanye Stillwater shares can be evaluated.
Sibanye Stillwater's "short interest ratio" (SIR) is the quantity of Sibanye Stillwater shares currently shorted divided by the average quantity of Sibanye Stillwater shares traded daily (recently around 3.8 million). Sibanye Stillwater's SIR currently stands at 2.31. In other words for every 100,000 Sibanye Stillwater shares traded daily on the market, roughly 2310 shares are currently held short.
However Sibanye Stillwater's short interest can also be evaluated against the total number of Sibanye Stillwater shares, or, against the total number of tradable Sibanye Stillwater shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sibanye Stillwater's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Sibanye Stillwater shares in existence, roughly 10 shares are currently held short) or 0.0127% of the tradable shares (for every 100,000 tradable Sibanye Stillwater shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sibanye Stillwater.
Find out more about how you can short Sibanye Stillwater stock.
Dividend payout ratio: 2.05% of net profits
Recently Sibanye Stillwater has paid out, on average, around 2.05% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 10.83% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Sibanye Stillwater shareholders could enjoy a 10.83% return on their shares, in the form of dividend payments. In Sibanye Stillwater's case, that would currently equate to about $6.13 per share.
While Sibanye Stillwater's payout ratio might seem low, this can signify that Sibanye Stillwater is investing more in its future growth.
Sibanye Stillwater's most recent dividend payout was on 29 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 15 September 2021 (the "ex-dividend date").
Sibanye Stillwater's shares were split on a 102:100 basis on 4 October 2017. So if you had owned 100 shares the day before before the split, the next day you'd have owned 102 shares. This wouldn't directly have changed the overall worth of your Sibanye Stillwater shares – just the quantity. However, indirectly, the new 2% lower share price could have impacted the market appetite for Sibanye Stillwater shares which in turn could have impacted Sibanye Stillwater's share price.
Over the last 12 months, Sibanye Stillwater's shares have ranged in value from as little as $9.9349 up to $19.5082. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Sibanye Stillwater's is 1.5077. This would suggest that Sibanye Stillwater's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sibanye Stillwater Limited operates as a precious metals mining company in South Africa, the United States, Zimbabwe, Canada, and Argentina. The company produces gold; platinum group metals (PGMs), including palladium, platinum, and rhodium; and by-products, such as iridium, ruthenium, nickel, copper, and chrome. It owns the East Boulder and Stillwater mines located in Montana, the United States; and Columbus metallurgical complex, which smelts the material mined to produce PGM-rich filter cake, as well as conducts PGM recycling activities. The company is also involved in the Kroondal, Rustenburg, Marikana, and Platinum Mile operations situated in South Africa; Mimosa located on the southern portion of the Great Dyke in Zimbabwe; the Driefontein, Kloof, and Cooke surface operations located on the West Rand of the Witwatersrand Basin; and the Beatrix situated in the southern Free State. In addition, it owns an interest in surface tailings retreatment facilities; the Marathon PGM project in Ontario, Canada; the Altar and Rio Grande copper gold projects in the Andes in north-west Argentina; the Hoedspruit and Zondernaam PGM projects in South Africa; and the Burnstone and southern Free State gold projects in South Africa. Sibanye Stillwater Limited was founded in 2013 and is based in Weltevreden Park, South Africa. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.